-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference, new drugs in the field of rheumatism and immunity emerge in endlessly and enter medical insurance, bringing greater benefits to patients.
In order to promote clinical and basic research in the field of rheumatology and immunology in my country, improve the information level of diagnosis, treatment and management of rheumatism The Center for Clinical Medicine Research of Diseases (NCRC-DID), the Chinese Association of Rheumatology and Immunology (CRCA), the National Rheumatology Data Center (CRDC), and the China Systemic Lupus Erythematosus Research Collaboration Group (CSTAR) co-sponsored the "First National Skin The annual meeting of the Clinical Medical Research Center for Immunological Diseases and the CSTAR/CRDC/CRCA Annual Meeting" has been held in Beijing on March 26, 2021.
The scene of the conference Figure 1 The first NCRC-DID annual conference: larger scale and more participants This conference gathered experts, scholars and related practitioners in the field of rheumatism and immunology from all over the country.
The venue was full and packed.
Professor Zeng Xiaofeng, director of NCRC-DID and director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, as the chairman of this conference, introduced the background and significance of the establishment of the conference to the "medical community".
Professor Zeng Xiaofeng said that the CSTAR annual conference has been held for 11 sessions, but unlike previous years, this conference is also the first NCRC-DID annual conference, with a larger scale and more participants, which is also a highlight of this year.
The conference is getting better and better, thanks to the country's attention and support in the field of rheumatism.
Especially in May 2019, NCRC-DID passed the certification of the fourth batch of national clinical medical research centers.
This major event marked the rapid development of rheumatism and immunology.
Professor Zeng Xiaofeng’s interview video 2 National academic exchanges are of great practical significance.
Professor Zeng Xiaofeng emphasized that this annual meeting is an academic exchange activity held at the national level.The conference mainly relies on the National Clinical Medicine Research Center to carry out popular science propaganda and academic exchanges, which effectively guarantees the scientific, cutting-edge and authoritative content of the content.
As the director of NCRC-DID, Professor Zeng Xiaofeng believes that the first NCRC-DID annual meeting has very important practical significance.
He said that the center's positioning is to face the needs of disease prevention and control, an organization that is clinically demand-oriented, and is based on medical institutions.
It relies on network support units to carry out its work through the National Clinical Medicine Research Center.
"Because the National Clinical Medicine Research Center is a clinical science and technology innovation base jointly established by the Ministry of Science and Technology, the Health Commission, the Military Commission, the Logistics Support Department, and the National Medical Products Administration.
It has a national mission.
The
mission of the center is to work actively.
, Complete various tasks assigned by the state, including large-scale clinical research, academic exchanges, talent training, discipline construction, medical big data, telemedicine, health poverty alleviation, popular science publicity, etc.
"3 new targets, new drugs, rheumatism patients Here comes the gospel.
Interleukin (IL)-17A is a key target for the treatment of ankylosing spondylitis (AS) discovered in recent years, and its targeted therapy program has triggered an upsurge in this field.
Previous studies have found that IL-17A, derived from innate immunity and adaptive immunity, plays a key role in the pathogenesis of AS: it is the main effector driving the chronic inflammation of AS, acting on a variety of downstream effector cells, and promoting cytokines and cytokines.
The release of chemokines triggers a series of pathological reactions such as inflammation, vascular activation, and matrix destruction; IL-17A is also a key cytokine that regulates the pathological process of AS enthesitis, which is the characteristic manifestation and basic pathology of AS change.
Studies have shown that Skukuzumab, which targets IL-17A, can regulate the pathological process of AS at multiple levels, inhibit inflammation and prevent structural damage; quickly relieve back pain, morning stiffness and fatigue symptoms; continue to relieve symptoms and reduce disease activity; improve Fat deposits, inhibit new bone formation.
In general, Skucilumab is used in the treatment of AS, which has a more comprehensive curative effect, a more direct effect, and a better safety, which can enable patients to obtain long-term relief and comprehensive benefits.
The conference also involved the academic progress of IL-17A.
Some speakers cited research data and pointed out that targeting IL-17A is a very effective path for patients with rheumatism such as AS.
Professor Zeng Xiaofeng is very optimistic about the clinical application prospects of these drugs.
He believes that AS and other diseases were once lack of medical treatment and medicine, and patients were faced with great difficulties in treatment.
With the development of science and technology, various biological agents are emerging one after another, and therapeutic drugs are becoming more and more abundant.
In particular, the emergence of IL-17A inhibitor drugs that act on new targets has brought good news to patients with AS.
Picture 4 of Professor Zeng Xiaofeng’s meeting site.
Good medicines are included in medical insurance, benefiting more rheumatism patients.
After the medical insurance policy is adjusted in 2021, a variety of innovative drugs in the field of rheumatism have been included in the national medical insurance catalog, which is undoubtedly another major good news for patients.
“In the past, AS was a disabling disease, because there were almost no drugs to treat, but now the drugs have been studied to prove that they can prevent disability, and standardized medication is of great significance to patients.
A
large number of evidence-based medical studies in the world have shown that drugs are effective in inhibiting the development of inflammation.
It has a very good effect on inhibiting the formation of new bones and osteophytes and inhibiting bone destruction.
The
availability of medicines is also very important.
It is very good that medicines are included in the medical insurance so that more patients can afford the medicines and benefit from them.
Things.
"Five disciplines are developing rapidly, and colleagues still need to work hard to communicate.
In the end, Professor Zeng Xiaofeng, as an authoritative expert in the field, put forward his expectations and messages to colleagues in rheumatism and immunity across the country.
"The Department of Rheumatology and Immunology is in a period of high and rapid development.
Next, I hope that the discipline can develop faster, become stronger and bigger, and meet the medical needs of patients with rheumatism and immunology across the country. "Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology, Peking Union Medical College Hospital, PhD student/postdoctoral supervisor, Member of the Beijing Municipal Committee of the Chinese People’s Political Consultative Conference, State Council Special Allowance Recipient, Chief Scientist of the National Key Research and Development Program of the 13th Five-Year Plan, Director, National Center for Clinical Research on Skin and Immune Diseases Vice Chairman of the Asia-Pacific Association of Rheumatology (APLAR) Executive Director of the Chinese Medical Doctor Association and Chairman of the Rheumatology Branch of the Chinese Medical Association 9th and 10th Chairman of the Rheumatology Branch of the Chinese Medical Association Vice Chairman of the Clinical Immunology Branch of the Chinese Society of Immunology, Chinese Rehabilitation Medicine Chairman of the Rheumatology Branch, Executive Director of the Cross-Strait Medical Exchange Association, Executive Director of Beijing Medical Association, in the past reviewed whether biological agents need to use loading doses? Clinical evidence has the final say! Taking the "unusual" road, IL-17A inhibitors have overcome all obstacles , Pursue excellence! The path of change in the treatment of ankylosing spondylitis: from "symptomatic treatment" to "full management", the new medical insurance catalogue is officially implemented.
What changes will it bring to the diagnosis and treatment of AS? The latest medical insurance drug list is implemented, IL-17A inhibitors will benefit more rigid patients! "Inflammation" must be lost, anti-inflammation knows how: IL-17A and inflammation
In order to promote clinical and basic research in the field of rheumatology and immunology in my country, improve the information level of diagnosis, treatment and management of rheumatism The Center for Clinical Medicine Research of Diseases (NCRC-DID), the Chinese Association of Rheumatology and Immunology (CRCA), the National Rheumatology Data Center (CRDC), and the China Systemic Lupus Erythematosus Research Collaboration Group (CSTAR) co-sponsored the "First National Skin The annual meeting of the Clinical Medical Research Center for Immunological Diseases and the CSTAR/CRDC/CRCA Annual Meeting" has been held in Beijing on March 26, 2021.
The scene of the conference Figure 1 The first NCRC-DID annual conference: larger scale and more participants This conference gathered experts, scholars and related practitioners in the field of rheumatism and immunology from all over the country.
The venue was full and packed.
Professor Zeng Xiaofeng, director of NCRC-DID and director of the Department of Rheumatology and Immunology of Peking Union Medical College Hospital, as the chairman of this conference, introduced the background and significance of the establishment of the conference to the "medical community".
Professor Zeng Xiaofeng said that the CSTAR annual conference has been held for 11 sessions, but unlike previous years, this conference is also the first NCRC-DID annual conference, with a larger scale and more participants, which is also a highlight of this year.
The conference is getting better and better, thanks to the country's attention and support in the field of rheumatism.
Especially in May 2019, NCRC-DID passed the certification of the fourth batch of national clinical medical research centers.
This major event marked the rapid development of rheumatism and immunology.
Professor Zeng Xiaofeng’s interview video 2 National academic exchanges are of great practical significance.
Professor Zeng Xiaofeng emphasized that this annual meeting is an academic exchange activity held at the national level.The conference mainly relies on the National Clinical Medicine Research Center to carry out popular science propaganda and academic exchanges, which effectively guarantees the scientific, cutting-edge and authoritative content of the content.
As the director of NCRC-DID, Professor Zeng Xiaofeng believes that the first NCRC-DID annual meeting has very important practical significance.
He said that the center's positioning is to face the needs of disease prevention and control, an organization that is clinically demand-oriented, and is based on medical institutions.
It relies on network support units to carry out its work through the National Clinical Medicine Research Center.
"Because the National Clinical Medicine Research Center is a clinical science and technology innovation base jointly established by the Ministry of Science and Technology, the Health Commission, the Military Commission, the Logistics Support Department, and the National Medical Products Administration.
It has a national mission.
The
mission of the center is to work actively.
, Complete various tasks assigned by the state, including large-scale clinical research, academic exchanges, talent training, discipline construction, medical big data, telemedicine, health poverty alleviation, popular science publicity, etc.
"3 new targets, new drugs, rheumatism patients Here comes the gospel.
Interleukin (IL)-17A is a key target for the treatment of ankylosing spondylitis (AS) discovered in recent years, and its targeted therapy program has triggered an upsurge in this field.
Previous studies have found that IL-17A, derived from innate immunity and adaptive immunity, plays a key role in the pathogenesis of AS: it is the main effector driving the chronic inflammation of AS, acting on a variety of downstream effector cells, and promoting cytokines and cytokines.
The release of chemokines triggers a series of pathological reactions such as inflammation, vascular activation, and matrix destruction; IL-17A is also a key cytokine that regulates the pathological process of AS enthesitis, which is the characteristic manifestation and basic pathology of AS change.
Studies have shown that Skukuzumab, which targets IL-17A, can regulate the pathological process of AS at multiple levels, inhibit inflammation and prevent structural damage; quickly relieve back pain, morning stiffness and fatigue symptoms; continue to relieve symptoms and reduce disease activity; improve Fat deposits, inhibit new bone formation.
In general, Skucilumab is used in the treatment of AS, which has a more comprehensive curative effect, a more direct effect, and a better safety, which can enable patients to obtain long-term relief and comprehensive benefits.
The conference also involved the academic progress of IL-17A.
Some speakers cited research data and pointed out that targeting IL-17A is a very effective path for patients with rheumatism such as AS.
Professor Zeng Xiaofeng is very optimistic about the clinical application prospects of these drugs.
He believes that AS and other diseases were once lack of medical treatment and medicine, and patients were faced with great difficulties in treatment.
With the development of science and technology, various biological agents are emerging one after another, and therapeutic drugs are becoming more and more abundant.
In particular, the emergence of IL-17A inhibitor drugs that act on new targets has brought good news to patients with AS.
Picture 4 of Professor Zeng Xiaofeng’s meeting site.
Good medicines are included in medical insurance, benefiting more rheumatism patients.
After the medical insurance policy is adjusted in 2021, a variety of innovative drugs in the field of rheumatism have been included in the national medical insurance catalog, which is undoubtedly another major good news for patients.
“In the past, AS was a disabling disease, because there were almost no drugs to treat, but now the drugs have been studied to prove that they can prevent disability, and standardized medication is of great significance to patients.
A
large number of evidence-based medical studies in the world have shown that drugs are effective in inhibiting the development of inflammation.
It has a very good effect on inhibiting the formation of new bones and osteophytes and inhibiting bone destruction.
The
availability of medicines is also very important.
It is very good that medicines are included in the medical insurance so that more patients can afford the medicines and benefit from them.
Things.
"Five disciplines are developing rapidly, and colleagues still need to work hard to communicate.
In the end, Professor Zeng Xiaofeng, as an authoritative expert in the field, put forward his expectations and messages to colleagues in rheumatism and immunity across the country.
"The Department of Rheumatology and Immunology is in a period of high and rapid development.
Next, I hope that the discipline can develop faster, become stronger and bigger, and meet the medical needs of patients with rheumatism and immunology across the country. "Professor Zeng Xiaofeng, Director of the Department of Rheumatology and Immunology, Peking Union Medical College Hospital, PhD student/postdoctoral supervisor, Member of the Beijing Municipal Committee of the Chinese People’s Political Consultative Conference, State Council Special Allowance Recipient, Chief Scientist of the National Key Research and Development Program of the 13th Five-Year Plan, Director, National Center for Clinical Research on Skin and Immune Diseases Vice Chairman of the Asia-Pacific Association of Rheumatology (APLAR) Executive Director of the Chinese Medical Doctor Association and Chairman of the Rheumatology Branch of the Chinese Medical Association 9th and 10th Chairman of the Rheumatology Branch of the Chinese Medical Association Vice Chairman of the Clinical Immunology Branch of the Chinese Society of Immunology, Chinese Rehabilitation Medicine Chairman of the Rheumatology Branch, Executive Director of the Cross-Strait Medical Exchange Association, Executive Director of Beijing Medical Association, in the past reviewed whether biological agents need to use loading doses? Clinical evidence has the final say! Taking the "unusual" road, IL-17A inhibitors have overcome all obstacles , Pursue excellence! The path of change in the treatment of ankylosing spondylitis: from "symptomatic treatment" to "full management", the new medical insurance catalogue is officially implemented.
What changes will it bring to the diagnosis and treatment of AS? The latest medical insurance drug list is implemented, IL-17A inhibitors will benefit more rigid patients! "Inflammation" must be lost, anti-inflammation knows how: IL-17A and inflammation
